BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) reported higher second-quarter revenue, largely on the strength of a recent asset-purchase agreement.

Brickell recorded revenue of $4.3 million, compared with $200,000 in the second quarter of 2021. Most of that — $3 million — came from an upfront payment from Botanix SB, a subsidiary of Botanix Pharmaceuticals Ltd., which acquired all of Brickell’s rights and assets to sofpironium bromide, a potential treatment for primary axillary hyperhidrosis, or excessive underarm sweating. Brickell was on track to submit a New Drug Application to the U.S. Food and Drug Administration for sofpironium bromide gel in mid-2022.

Brickell will receive upfront and near-term regulatory milestone payments of up to $9 million from Botanix, with additional success-based regulatory and sales milestone payments of up to $168 million.

Brickell’s net loss for the second quarter totaled $1 million, down from $11.1 million in the same period a year ago.

The company in July effected a 1-for-45 reverse stock split to regain compliance with the Nasdaq Capital Market for minimum stock price. Brickell’s stock closed Thursday at $3.27.

BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) reported higher second-quarter revenue, largely on the strength of a recent asset-purchase agreement.

Brickell recorded revenue of $4.3 million, compared with $200,000 in the second quarter of 2021. Most of that — $3 million — came from an upfront payment from Botanix SB, a subsidiary of Botanix Pharmaceuticals Ltd., which acquired all of Brickell’s rights and assets to sofpironium bromide, a potential treatment for primary axillary hyperhidrosis, or excessive underarm sweating. Brickell was on track to submit a New Drug Application to the U.S. Food and Drug Administration for sofpironium bromide gel in mid-2022.

This article has been intentionally blurred. You must purchase a subscription to view the rest of this content.

If you canceled your payment, click here to close this window.

If you processed a payment and this page does not reload in 10 seconds, please reach out to Bruce Dennis at 303-630-1953 for additional assistance.

The contents of this website are copyright BizWest Media, LLC. All rights reserved.

Use of any of this information or media on this site is strictly prohibited without express written consent.